Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 11/20 | 0.63 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.63 |
| ▸ | KHK | P50053 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27167868 | 1.00 | DDB1 (0.63) | DDB1CRBNKHKPDE4BHTR3A | |
| SCHEMBL29976687 | 1.00 | DDB1 (0.63) | DDB1CRBNKHKPDE4BHTR3A | |
| SCHEMBL27167811 | 1.00 | DDB1 (0.63) | DDB1CRBNKHKPDE4BHTR3A | |
| SCHEMBL27168231 | 0.95 | DDB1 (0.62) | DDB1CRBNKCNH2HRH4HRH3 | |
| SCHEMBL27167653 | 0.95 | DDB1 (0.62) | DDB1CRBNKCNH2HRH4HRH3 | |
| SCHEMBL29976664 | 0.95 | DDB1 (0.62) | DDB1CRBNKCNH2HRH4HRH3 | |
| SCHEMBL23551326 | 0.94 | DDB1 (0.65) | DDB1CRBNKHKKCNH2HRH4 | |
| Hydrochloric Acid SCHEMBL29744718 | 0.93 | DDB1 (0.64) | DDB1CRBNKHKKCNH2HRH4 | |
| Hydrochloric Acid SCHEMBL23538499 | 0.93 | DDB1 (0.64) | DDB1CRBNKHKKCNH2HRH4 | |
| SCHEMBL31160706 | 0.92 | CRBN (0.68) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | C4 THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4333899-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022235945-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | DDB1 729/4885CRBN 166/4885KHK 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.